CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Johnson & Johnson Kenvue spinoff: JNJ consumer health division business separation date and details

By Jenny McCall

11:43, 17 October 2022

A image of JNJ baby powder
J&J will separate from its consumer division and form a new publicly traded company - Photo: Getty Images

Health and pharmaceutical giant Johnson & Johnson (JNJ) is following in the footsteps of its competitor GlaxoSmithKline (GSK) and spinning-off its consumer healthcare division.

The new company will be called Kenvue and JNJ revealed in September that it got its inspiration for the new name from Scotland, as “ken” refers to knowledge, while “vue” relates to sight.

What is your sentiment on JNJ?

157.09
Bullish
or
Bearish
Vote to see Traders sentiment!

Johnson & Johnson (JNJ) share price chart

JNJ to spin-off its consumer health division

“The new corporate brand comes to life through a compelling purpose, and a timeless visual brand,” J&J said in its release.

Well, it seems that compelling is the word of the day for JNJ’s consumer division as it accounted for $14.6bn (£12.9bn) (16%) of J&J’s revenue in 2021. The segment is home to a host of well-known products such as Aveeno, Band-Aid, Listerine, Neutrogena, and Tylenol.

It was in November that JNJ first revealed that it would separate from its consumer division and form a new publicly traded company.

“Following a comprehensive review, the board and management team believe that the planned separation of the consumer health business is the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth, and – most importantly – improve healthcare outcomes for people around the world,” Alex Gorsky Executive Chairman of Johnson & Johnson said in a press release.

JNJ's share price has been down 3% this year, as it grapples, like many other organisations, with rising production costs, interest rates and recession woes. With this spin-off going ahead, the hope is it will revive JNJ’s share price. Here are the details in full.

TSLA

247.19 Price
-3.310% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 0.15

NVDA

118.39 Price
-6.290% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 0.12

AAPL

229.38 Price
-2.140% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 0.11

AMD

161.58 Price
-8.730% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 0.12

GlaxoSmithKline (GSK) share price history

1m
5m
15m
30m
1H
4H
1D
1W

How much revenue will the spin-off generate?

The spin-off is expected to generate between $500m to $1bn.

When will the spin-off be complete?

The spin-off is forecast to complete by November 2023 and began in November 2021. It has been given a timeframe of 18 to 24 months.

Why is JNJ splitting?

JNJ is trying to streamline its business and removing its consumer arm will enable it to do this. JNJ wants to invest more into its medicines and medical devices divisions, which brought in $80bn combined in 2021. Despite JNJ’s poor sales with its Covid-19 vaccine, its medicine segment still brings in more growth than its consumer business.

What will happen to JNJ stock once the split is complete?

Once the spin-off is complete the new company will trade separately and the JNJ split is expected to make more shareholder returns, as each business will not be diluted by the other segments. JNJ shares currently trade at $164.46.

What will the spin-off mean for shareholders?

Current JNJ shareholders will still own shares in JNJ and once the split takes place, they will own shares in the new company as well.

JNJ also said: “In addition, it is expected that the overall shareholder dividend will remain at least at the same level following the completion of the transaction.”

Markets in this article

GSKl
GSK
15.350 USD
0.31 +2.070%
JNJ
Johnson & Johnson (Extended Hours)
157.09 USD
6.01 +3.980%

Related topics

Rate this article

Related reading

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided in this article is for information purposes only and should not be understood as investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents and has not been prepared in accordance with the legal requirements designed to promote investment research independence. While the information in this communication, or on which this communication is based, has been obtained from sources that Capital.com believes to be reliable and accurate, it has not undergone independent verification. No representation or warranty, whether expressed or implied, is made as to the accuracy or completeness of any information obtained from third parties. If you rely on the information on this page, then you do so entirely at your own risk.

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading